Page last updated: 2024-11-08

1,2-oleoylphosphatidylcholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

1,2-oleoylphosphatidylcholine: RN given refers to (Z,Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dioleoyl phosphatidylcholine : A phosphatidylcholine in which the phosphatidyl acyl groups are both oleoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5313476
CHEBI ID60428
SCHEMBL ID4991832
MeSH IDM0067888

Synonyms (19)

Synonym
1,2-dioleoylglycerophosphocholine
dielaidoylphosphatidylcholine
dielaidinoyl lecithin
dioleoyl lecithin
1,2-oleoylphosphatidylcholine
1,2-docpc
1,2-dioleoyl glycerophosphocholine
dioleoyl phosphatidylcholine
1,2-dioleoylglycerol-3-phosphorylcholine
CHEBI:60428 ,
(18z)-4-hydroxy-n,n,n-trimethyl-7-[(9z)-octadec-9-enoyloxy]-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide
1,2-dioleoyllecithin
1,2-dioleoylglyceryl-3-phosphorylcholine
1-(9z-octadecenoyl)-2-(9z-octadecenoyl)-sn-glycero-3-phosphocholine
pc(18:1(9z)/18:1(9z))[u]
2-[2,3-bis[[(z)-octadec-9-enoyl]oxy]propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium
EPITOPE ID:136903
SCHEMBL4991832
Q27127274

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A modified 'amyloid cascade' hypothesis for Alzheimer's disease states that prefibrillar oligomers, also called amyloid-beta-derived diffusible ligands or globular oligomers, are the responsible toxic agent."( Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity.
Anderluh, G; Ceru, S; Gutierrez-Aguirre, I; Kopitar-Jerala, N; Macek, P; Rabzelj, S; Turk, V; Zerovnik, E, 2005
)
0.33
" However, whether the membrane is among their direct targets, that mediate the downstream adverse effects, remains a question of debate."( Membrane interaction of off-pathway prion oligomers and lipid-induced on-pathway intermediates during prion conversion: A clue for neurotoxicity.
Combet, S; Cousin, F; Noinville, S; Rezaei, H, 2019
)
0.51
" Here we report an easy and robust method to generate toxic hIAPP oligomers, which are stable for at least 8 hours."( Deformation of stable and toxic hIAPP oligomers by liposomes with distinct nanomechanical features and reduced cytotoxicity.
Chen, Q; Feng, Y; Li, P; Liu, L; Mao, X; Wang, J; Yuan, L; Zhang, L, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetics following intramuscular injection of the multivesicular liposome of thymopentin labeled with fluorescein isothiocyanate in rats showed that the peak concentration of thymopentin was lower and elimination of it was slower significantly than that of thymopentin labeled with fluorescein isothiocyanate solution in the same dose."( [Preparation of sustained release multivesicular liposome for thymopentin and preliminary study on its pharmacokinetics in rats].
Jiao, YH; Mu, HJ; Sun, KX; Wang, T; Yao, DG; Yuan, ZZ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"To examine the transport of an ionic substance through a bilayer lipid membrane (BLM), an electrochemical method combined with fluorometry was proposed."( Dynamic behavior analysis of ion transport through a bilayer lipid membrane by an electrochemical method combined with fluorometry.
Fukuyama, M; Hori, K; Maeda, K; Murakami, K; Naka, Y; Omatsu, T; Sakai, K; Shimazaki, M; Yoshida, Y, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Immune activation was decreased 2 orders of magnitude below controls, and pharmacokinetic bioavailability improved by a factor of 17."( Virus-inspired membrane encapsulation of DNA nanostructures to achieve in vivo stability.
Perrault, SD; Shih, WM, 2014
)
0.4
" However, the instability and low bioavailability of gold nanoparticles compromise their clinical application."( Increased cellular uptake of peptide-modified PEGylated gold nanoparticles.
Dai, W; He, B; Qin, M; Wang, X; Yang, D; Yin, C; Zhang, H; Zhang, Q; Zhang, Y, 2017
)
0.46
" This study clarifies the mechanism of increasing the drug's bioavailability in the presence of glycyrrhizin."( Glycyrrhizin-Assisted Transport of Praziquantel Anthelmintic Drug through the Lipid Membrane: An Experiment and MD Simulation.
Dushkin, AV; Kim, AV; Lyakhov, NZ; Medvedev, NN; Meteleva, ES; Polyakov, NE; Selyutina, OY; Shelepova, EA, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Dose-response of intraventricular injection of liposomal NGF showed significant reduction in infarct volume at the dose of 5 and 10 microg/rat of NGF."( Treatment of focal cerebral ischemia with liposomal nerve growth factor.
Chen, WY; Chern, CM; Hsu, LC; Hu, HH; Huang, KJ; Law, SL; Luk, YO; Wong, WJ,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphatidylcholine(1+)A glycerophosphocholine compound having O-acyl substituents at both the 1- and 2-positions of the glycerol. It is a major constituent of cell membranes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (1,988)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990146 (7.34)18.7374
1990's353 (17.76)18.2507
2000's596 (29.98)29.6817
2010's799 (40.19)24.3611
2020's94 (4.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews13 (0.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2,003 (99.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]